• A
  • A
  • A
日本語 Help
Science and technology information site for articles, patents, researchers information, etc.

Co-authoring Researcher

Co-inventing Researcher

Researcher similar to the Researcher

Article similar to the Researcher

Patent similar to the Researcher

Research Project similar to the Researcher

Article(J-GLOBAL estimation)

Patent(J-GLOBAL estimation)

Rchr
J-GLOBAL ID:201301034308637959   Update date: Jan. 17, 2025

Ryohei Katayama

カタヤマ リョウヘイ | Ryohei Katayama
Clips
Affiliation and department:
Job title: 部長
Homepage URL  (1): http://kaken.nii.ac.jp/d/r/60435542.ja.html
Research field  (2): Tumor biology ,  Pathobiochemistry
Research keywords  (9): cancer immunotherapy ,  molecular targeted cancer therapy ,  多剤耐性 ,  がん幹細胞 ,  ABCトランスポーター ,  acquired resistance ,  cancer ,  薬学 ,  cellular signal transduction
Research theme for competitive and other funds  (16):
  • 2022 - 2026 Searching druggable target sites by developing refined molecular dynamic simulations
  • 2022 - 2024 Oct4陽性肺癌幹細胞マウスモデルの樹立と癌幹細胞を根絶する革新的治療法の開発
  • 2020 - 2024 臨床がんの遺伝子情報維持に必要な物理化学的因子の解明とがん個別化医療への応用
  • 2020 - 2022 Molecular mechanisms of paradoxical growth suppression by over activation of oncogene kinases
  • 2019 - 2022 Analysis of the drug persistent cells to understand the acquired resistance mechanisms in lung cancer
Show all
Papers (108):
  • Kohei Maruyama, Yuki Shimizu, Yumi Nomura, Tomoko Oh-Hara, Yuki Takahashi, Satoshi Nagayama, Naoya Fujita, Ryohei Katayama. Mechanisms of KRAS inhibitor resistance in KRAS-mutant colorectal cancer harboring Her2 amplification and aberrant KRAS localization. NPJ precision oncology. 2025. 9. 1. 4-4
  • Satoshi Takagi, Mikako Nakajima, Sumie Koike, Miho Takami, Yoshiya Sugiura, Seiji Sakata, Satoko Baba, Ai Takemoto, Tianyi Huang, Yosuke Seto, et al. Frequent copy number gain of MCL1 is a therapeutic target for osteosarcoma. Oncogene. 2024
  • Yuki Oyama, Kentaro Shimada, Haruhiko Miyata, Rie Iida-Norita, Chihiro Emori, Maki Kamoshita, Seiya Oura, Ryohei Katayama, Martin M Matzuk, Masahito Ikawa. Inhibition of ROS1 activity with lorlatinib reversibly suppresses fertility in male mice. Andrology. 2024
  • Takaaki Fujimura, Koh Furugaki, Hayato Mizuta, Satoshi Muraoka, Makoto Nishio, Jun Adachi, Ken Uchibori, Eisaku Miyauchi, Hidetoshi Hayashi, Ryohei Katayama, et al. Targeting ErbB and tankyrase1/2 prevent the emergence of drug-tolerant persister cells in ALK-positive lung cancer. NPJ precision oncology. 2024. 8. 1. 264-264
  • Koh Furugaki, Takaaki Fujimura, Narumi Sakaguchi, Yasutaka Watanabe, Ken Uchibori, Eisaku Miyauchi, Hidetoshi Hayashi, Ryohei Katayama, Shigeki Yoshiura. Combined blockade of GPX4 and activated EGFR/HER3 bypass pathways inhibits the development of ALK-inhibitor-induced tolerant persister cells in ALK-fusion-positive lung cancer. Molecular oncology. 2024
more...
MISC (35):
  • 藤村 多嘉朗, 横山 俊秀, 内堀 健, 宮内 栄作, 林 秀敏, 片山 量平. 患者由来ALK融合遺伝子陽性肺がん細胞株を用いたdrug tolerant persisterに対する新規併用療法の探索. 肺癌. 2022. 62. 6. 654-654
  • 片山量平, きょう博, 清谷一馬, 西尾誠人, 竹内賢吾, 藤田直也. 臨床検体と同系マウスゼノグラフトモデルを駆使した抗PD-L1抗体耐性機構の探索. 日本免疫治療学会学術集会プログラム・抄録集. 2020. 17th
  • Bo Gong, Kazuma Kiyotani, Seiji Sakata, Ken Takahashi, Seiji Nagano, Shun Kumehara, Satoko Baba, Benjamin Besse, Noriko Yanagitani, Luc Friboulet, et al. Identification of secreted PD-L1 variants as a decoy of PD-L1 blockade antibody mediating the therapeutic resistance. MOLECULAR CANCER THERAPEUTICS. 2019. 18. 12
  • Koutaroh Okada, Mitsugu Araki, Tomoko Oh-hara, Makoto Nishio, Yasushi Okuno, Naoya Fujita, Ryohei Katayama. Predication of lorlatinib resistance mechanisms and therapeutic strategies to overcome the resistance in ALK rearranged non-small cell lung cancer. MOLECULAR CANCER THERAPEUTICS. 2019. 18. 12
  • 片山量平, キョウ ハク, 清谷一馬, 竹内賢吾, 西尾誠人, 藤田直也. 免疫チェックポイント阻害薬抵抗腫瘍の多様性と治療抵抗性機構の解析. 日本がん免疫学会総会プログラム・抄録集. 2019. 23rd
more...
Patents (24):
Education (3):
  • 2003 - 2006 The University of Tokyo Graduate School of Pharmaceutical Sciences Department of Pharmaceutical Technology
  • 2001 - 2003 The University of Tokyo Graduate School of Pharmaceutical Sciences Department of Pharmaceutical Technology
  • 1997 - 2001 The University of Tokyo Faculty of Pharmaceutical Sciences
Work history (5):
  • 2017/10 - 現在 Japanese Foundation for Cancer Research Cancer Chemotherapy Center Chief
  • 2015/10 - 2017/09 Japanese Foundation for Cancer Research Cancer Chemotherapy Center Senior Staff Scientist
  • 2012/07 - 2015/09 Japanese Foundation for Cancer Research Cancer Chemotherapy Center Staff Scientist
  • 2010/04 - 2012/07 Massachusetts General Hospital Cancer Center Postdoc research fellow (JSPS fellowship)
  • 2006/04 - 2010/03 財団法人癌研究会 癌化学療法センター基礎研究部 研究員
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page